| Literature DB >> 32591385 |
Michał Dmowski1, Izabela Kern-Zdanowicz2.
Abstract
Conjugative plasmids are the main players in horizontal gene transfer in Gram-negative bacteria. DNA transfer tools constructed on the basis of such plasmids enable gene manipulation even in strains of clinical or environmental origin, which are often difficult to work with. The conjugation system of the IncM plasmid pCTX-M3 isolated from a clinical strain of Citrobacter freundii has been shown to enable efficient mobilization of oriT pCTX-M3-bearing plasmids into a broad range of hosts comprising Alpha-, Beta-, and Gammaproteobacteria We constructed a helper plasmid, pMOBS, mediating such mobilization with an efficiency up to 1,000-fold higher than that achieved with native pCTX-M3. We also constructed Escherichia coli donor strains with chromosome-integrated conjugative transfer genes: S14 and S15, devoid of one putative regulator (orf35) of the pCTX-M3 tra genes, and S25 and S26, devoid of two putative regulators (orf35 and orf36) of the pCTX-M3 tra genes. Strains S14 and S15 and strains S25 and S26 are, respectively, up to 100 and 1,000 times more efficient in mobilization than pCTX-M3. Moreover, they also enable plasmid mobilization into the Gram-positive bacteria Bacillus subtilis and Lactococcus lactis Additionally, the constructed E. coli strains carried no antibiotic resistance genes that are present in pCTX-M3 to facilitate manipulations with antibiotic-resistant recipient strains, such as those of clinical origin. To demonstrate possible application of the constructed tool, an antibacterial conjugation-based system was designed. Strain S26 was used for introduction of a mobilizable plasmid coding for a toxin, resulting in the elimination of over 90% of recipient E. coli cells.IMPORTANCE The conjugation of donor and recipient bacterial cells resulting in conjugative transfer of mobilizable plasmids is the preferred method enabling the introduction of DNA into strains for which other transfer methods are difficult to establish (e.g., clinical strains). We have constructed E. coli strains carrying the conjugation system of the IncM plasmid pCTX-M3 integrated into the chromosome. To increase the mobilization efficiency up to 1,000-fold, two putative regulators of this system, orf35 and orf36, were disabled. The constructed strains broaden the repertoire of tools for the introduction of DNA into the Gram-negative Alpha-, Beta-, and Gammaproteobacteria, as well as into Gram-positive bacteria such as Bacillus subtilis and Lactococcus lactis The antibacterial procedure based on conjugation with the use of the orf35- and orf36-deficient strain lowered the recipient cell number by over 90% owing to the mobilizable plasmid-encoded toxin.Entities:
Keywords: IncM plasmid; conjugative transfer; helper strain; plasmid mobilization
Mesh:
Substances:
Year: 2020 PMID: 32591385 PMCID: PMC7440800 DOI: 10.1128/AEM.01205-20
Source DB: PubMed Journal: Appl Environ Microbiol ISSN: 0099-2240 Impact factor: 4.792
Plasmids used in this work
| Group and name | Relevant feature or construction description | Reference(s) or source |
|---|---|---|
| pCTX-M3 and its derivative | ||
| pCTX-M3 | IncM plasmid, 89,468 bp; Apr Pir Aztr Cazr Cftr Kmr Genr Tor | |
| pCTX-M3 | pCTX-M3 with | |
| Cloning vectors | ||
| pABB19 | Cloning vector, | |
| pACYC184 | Cloning vector, | |
| pAL3 | Cloning vector | |
| pBAD24 | Vector, | |
| pBBR1 MCS-2 | Vector, | |
| pBSU100 | ||
| pBSU1 | pBSU100 with deleted | This work |
| pCP20 | Flp recombinase expression plasmid, | |
| pET28a+ | Vector, | Novagen |
| pKD3 | Template for generation of the | |
| pKD46 | λRed recombinase expression plasmid, | |
| pLDR8 | Helper plasmid for integration, | |
| pLDR10 | Vector for integration into | |
| pUC18 | Cloning vector, | |
| pUC19 | Cloning vector, | |
| Plasmids carrying | ||
| pALoriT | pOriT EcoRI-PstI fragment containing | This work |
| pABB19oriT | pOriT BamHI-PstI fragment containing | This work |
| pBBToriT | pALoriT XbaI-PvuI fragment containing tetracycline resistance gene and | This work |
| pBSUoriT | pOriT PaeI-SacI fragment containing | This work |
| pOriT | ||
| pToriT | pBBToriT derivative, fragment BsaI-Bst1107I with | This work |
| Plasmids used for | ||
| pALAP | pAL-SP3 SpeI-PstI fragment cloned into SpeI-PstI of pAL-AS14 | This work |
| pALAPK1 | pET28a+ fragment (3943–4832), contains kanamycin resistance gene amplified with primers FKanSpe2 and RKanSpe (SpeI) cloned into SpeI of pALAP | This work |
| pAL-AS14 | pLMAB212 fragment (92–359) amplified with primers FAatII and RnicSpe, cloned into SmaI of pAL3 | This work |
| pAL-SP3 | pLMAB212 fragment (356–1622) amplified with primers FnicSpe and RPshAI, cloned into SmaI of pAL3 | This work |
| pBS3-1 | pCTX-M3 minireplicon, fragment Bst1107I-StuI (54309–57986) | This work |
| pHS11 | pCTX-M3 derivative SexAI-SnaBI (36645–40568) | This work |
| pLD1 | pLDR10 derivative, removed fragment BsmI (1713–2120) | This work |
| pLDAB | pUCA3218 HindIII-BamHI fragment cloned into HindIII-BamHI of pLDB | This work |
| pLDB | pUCB3219B EcoRI-BamHI fragment cloned into EcoRI-BamHI of pLD1 | This work |
| pLMAB2 | pBS3-1 (3624–2152) fragment containing pCTX-M3 replicon, amplified with primers FRepCNI and RepANB2 (NotI), cloned into NotI of pLDAB | This work |
| pLMAB202 | pSN17 Bsp1407I (11410–14854; 84420–87864) | This work |
| pLMAB212 | AatII-NheI pSS29 fragment cloned into AatII-NheI of pLMAB202, | This work |
| pMOBS | pMOBSK derivative, removed the SpeI-SpeI fragment with the kanamycin resistance gene, | This work |
| pMOBSK | pALAPK1 AatII-PshAI fragment cloned into AatII-PshAI of pLMAB212 | This work |
| pSN17 | pCTX-M3 | This work |
| pSS29 | pCTX-M3 derivative, SwaI-SalI (30630–59552) | This work |
| pUCA0118 | pCTX-M3 (31285–32022) | This work |
| pUCA0218 | pCTX-M3 (52154–54408) | This work |
| pUCA0318 | pUCA0118 derivative with substitutions in the | This work |
| pUCA3218 | KpnI-SalI pUCA0218 fragment cloned into KpnI-SalI of pUCA0318 | This work |
| pUCB0219 | pCTX-M3 (87807–89020) | This work |
| pUCB0318 | pCTX-M3 | This work |
| pUCB3219 | SalI-KpnI pUCB0318 fragment cloned into SalI-KpnI of pUCB0219 | This work |
| pUCB3219B | pUCB3219 derivative, fragment Bsp1407I (1543–1729) removed | This work |
| Plasmids harboring | ||
| pUC-epsi | pACE1 EcoRI-HincII fragment containing | This work |
| pUC-epsiSH | Shortened pUCepsi after Bsp119I and EheI digestion; the sticky ends were blunted and religated; | This work |
| pBT233 | pSM19035 derivative, accession no. | |
| pET-zeta12 | pET28a+ with | This work |
| pACYC-zeta | pACYC184 with | This work |
| pACE1 | pACYC184 with | |
| pAZA | pACYC-zeta with | This work |
| pAZAKT | pAZA with | This work |
| pAAKT | pAZAKT SpeI digested, filled in, recircularized, inactive | This work |
Ap, ampicillin; Azt, aztreonam; Cft, cefotaxime; Caz, ceftazidime; Cm, chloramphenicol; Gen, gentamicin; Pi, piperacillin; Sp, spectinomycin; Tc, tetracycline; To, tobramycin; Ts, thermosensitive. Primers are listed in Table 3.
pCTX-M3 coordinates (accession no. AF550415).
Primers used in this work
| Function and name | Sequence (5′ → 3′) | PCR template |
|---|---|---|
| FtraHind | CATACCCTTTCG | pCTX-M3 |
| RtraPst | CTCCTG | pCTX-M3 |
| FnicM | GTACGGGACAATATTGGTTTTTGGAGTACCGC | pCTX-M3 |
| RnicM | CTCCAAAAACCAATATTGTCCCGTACTTAAATACC | pCTX-M3 |
| FtraSal | GCAGG | pCTX-M3 |
| RtraXba | ACTCTC | pCTX-M3 |
| FtrbXba | AGA | pCTX-M3 |
| RtrbBam | TTCCA | pCTX-M3 |
| FtrbNco-Sac | CGGTT | pCTX-M3 |
| RtrbEco | AATA | pCTX-M3 |
| FrepCNI | GTGGCGGCCGCGTAAGAAACCATTATTATC | pBS3-1 |
| RrepANB2 | TAGGCGGCCGCGGTCTCGCACCCCTGCCGTCTTACG | pBS3-1 |
| Nick region mutagenesis | ||
| FAatII | TTCT | pLMAB212 |
| RnicSpe | AACCGA | pLMAB212 |
| FKanSpe2 | GA | pET28a+ |
| RKanSpe | AG | pET28a+ |
| FnicSpe | GG | pLMAB212 |
| RPshAI | GAA | pLMAB212 |
| Kan- | ||
| FKanAatII | ATG | pToriTB |
| oriTminDAatII | TTG | pToriTB |
| orf36uP1 | ATGCAAACAGTGATGCATTCCCGTTCCATTTGTAACGTGTAGGCTGGAGCTGCTTCG | pKD3 |
| orf36dP2 | GAACAATGAGGTATACATGAGCGAACATAATGATTATATATGAATATCCTCCTTA | pKD3 |
| Integration verification | ||
| ybhB122 | CTGGCAAGCGCCTCGATTAC | |
| ybhC159 | ACCAGGCGCGGTTTGATCAG | |
| orf35UEc | TCGAATTCGACATTATTGGGAGGGC | |
| FtrbNco-Sac | CGGTT | |
| pCTX96 | CCGAGTCAGTTTGATCCATA | |
| orf36sU | GGATGAGGTATGCAATACGG | |
| Cloning of | ||
| EcoZetaFor | GCC | pBT233 |
| ZetaRevBam | GCC | |
| Cloning of | ||
| upTEM | CACCAGCGTTTCTGGGTGAG | pBAD24 |
| ARA1down | GC | |
| EpsiS | TGAA | |
| EpsiE | TGCCATA |
Relevant restriction sites are underlined. epsilon gene start and stop codons are in bold.
FIG 1Conjugation and pALoriT (oriTpCTX-M3 oriVp15A Tcr) mobilization efficiencies from E. coli donors with pLMAB212 or pMOBS into the JE2571Rifr recipient. Each result is the mean from four experiments. #, undetectable transfer. Error bars indicate standard deviations (SD).
Bacterial strains used in this study
| Species | Strain | Genotype or relevant feature | Source and/or reference |
|---|---|---|---|
| DH5α | ϕ80 | ||
| DH5αRifr | DH5α selected on LB with rifampicin | This work | |
| JE2571Rifr | JE2571 selected on LB with rifampicin | ||
| S14 | DH5α with the pCTX-M3 | This work | |
| S15 | S14 with | This work | |
| S25 | S15 with | This work | |
| S26 | S25 with Δ | This work | |
| 1149/2004 | Clinical isolate; Apr Tcr Strr; replicons IncFIB, IncI1, IncP | Collection of National Institute of Medicines ( | |
| 1355/2004 | Clinical isolate; Apr Tcr Strr; replicon IncP | Collection of National Institute of Medicines ( | |
| YB1015 | |||
| YB1015Rifr | YB1015 selected on LB with rifampicin | This work | |
| PCM2021 | Biofilm-forming strain | Polish Collection of Microorganisms | |
| PCM2021Rifr | PCM2021 selected on LB with rifampicin | This work | |
| IL1403 | |||
| IL1403Rifr | IL1403 selected on GM17 with rifampicin | This work | |
| LBA1010 | Rifr | ||
| KT2442 | Rifr | ||
| JMP228 | Rifr
|
FIG 2Mobilization efficiency of pToriT from strains DH5α(pCTX-M3), DH5α(pMOBS), and S14 into E. coli JE2571Rifr. Each result is the mean from four experiments. Error bars indicate SD.
FIG 3Mobilization efficiency of pToriT by strains S14, S15, S25, and S26 into E. coli JE2571Rifr and by S15 and S26 into different Proteobacteria recipients. Each result is the mean from four experiments. Error bars indicate SD.
FIG 4Mobilization efficiency of pBSUoriT from strain S25 into the Gram-positive recipients B. subtilis (A) and L. lactis (B). For comparison, efficiency of plasmid mobilization into E. coli JE2571Rifr is shown. Each result is the mean from four experiments. Error bars indicate SD.
FIG 5Mobilization efficiencies of pAZAKT and pAAKT by strain S26(pUC-epsi) into E. coli recipients JE2571Rifr and DH5αRifr. Each result is the mean from four experiments. Error bars indicate SD.
FIG 6Mobilization-mediated Zeta killing. Mobilization of pAZAKT or pAAKT from the S26(pUC-epsi) donor into E. coli JE2571Rifr as a recipient in stationary growth phase (A) and exponential growth phase (B) with various donor-to-recipient ratios is shown. Each result is the mean from three experiments. Error bars indicate SD.
FIG 7Mobilization efficiency of pToriT from strain S26 into clinical E. coli strains 1355/2004 and 1149/2004. For comparison, efficiency of plasmid mobilization into E. coli JE2571Rifr is shown. Each result is the mean from four experiments. Error bars indicate SD.
FIG 8Effect of mobilization of pAZAKT and pAAKT from the S26(pUC-epsi) donor into clinical strains 1149/2004 and 1355/2004 (A) and JE2571Rifr carrying the IncP plasmid from strain 1355/2004 (R+[E. coli 1355/2004]) (B). For comparison, efficiency of plasmid mobilization into E. coli JE2571Rifr is shown. Each result is the mean from at least three experiments. Error bars indicate SD.